Literature DB >> 18089417

Successful ABO incompatible living donor liver transplantation in a patient with high isoagglutinin titer using high-dose intravenous immunoglobulin.

T Ikegami1, A Taketomi, Y Soejima, T Iguchi, K Sanefuji, H Kayashima, T Yoshizumi, N Harada, Y Maehara.   

Abstract

The optimal management in living donor liver transplantation using an ABO incompatible donor with a high isoagglutinin titer is still uncertain. Our patient was a 20-year-old woman with fulminant hepatitis. The only available donor was her 54-year-old father-in-law of an incompatible blood type. The initial isoagglutinin titer was 2048x. She received 375 mg/m2 of anti-CD20 antibody 3 days before the living donor liver transplantation with concomitant splenectomy. Despite daily plasma exchanges after transplantation, the isoagglutinin titer started to shoot up to its maximum value of 2048x, with a sudden decline in the bile output. High-dose intravenous immunoglobulin (0.6 g/kg) was given after the plasma exchanges; thereafter, her liver function tests stabilized without a further increase in the isoagglutinin titer. We showed the effectiveness of high-dose intravenous immunoglobulin for the management of the rebound elevation of isoagglutinin titer. The combination of anti-CD20 antibody and daily plasma exchanges seemed ineffective for such a situation. This strategy might be another management option for ABO incompatible liver transplantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18089417     DOI: 10.1016/j.transproceed.2007.09.028

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

Review 1.  Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation.

Authors:  Arno Kornberg
Journal:  World J Hepatol       Date:  2015-06-18

2.  Feasible usage of ABO incompatible grafts in living donor liver transplantation.

Authors:  Toru Ikegami; Tomoharu Yoshizumi; Yuji Soejima; Hideaki Uchiyama; Ken Shirabe; Yoshihiko Maehara
Journal:  Hepatobiliary Surg Nutr       Date:  2016-04       Impact factor: 7.293

3.  The predictive value of blood neutrophil-lymphocyte ratio in patients with end-stage liver cirrhosis following ABO-incompatible liver transplantation.

Authors:  Bingyi Lin; Lei Geng; Zhiyun Zheng; Junjun Jia; Tian Shen; Jing Zhang; Lin Zhou; Shusen Zheng
Journal:  J Res Med Sci       Date:  2016-09-01       Impact factor: 1.852

4.  No diffuse intrahepatic biliary stricture after ABO-incompatible adult living donor liver transplantation using tailored rituximab-based desensitization protocol.

Authors:  Koji Natsuda; Takahiro Murokawa; Kwang-Woong Lee; Kyung Chul Yoon; Suk Kyun Hong; Jeong-Moo Lee; Jae-Hyung Cho; Nam-Joon Yi; Kyung-Suk Suh
Journal:  Ann Transl Med       Date:  2021-01

Review 5.  Feasibility of using marginal liver grafts in living donor liver transplantation.

Authors:  Xiang Lan; Hua Zhang; Hong-Yu Li; Ke-Fei Chen; Fei Liu; Yong-Gang Wei; Bo Li
Journal:  World J Gastroenterol       Date:  2018-06-21       Impact factor: 5.742

6.  Rituximab Desensitization in Liver Transplant Recipients With Preformed Donor-specific HLA Antibodies: A Japanese Nationwide Survey.

Authors:  Nobuhisa Akamatsu; Kiyoshi Hasegawa; Seisuke Sakamoto; Hideki Ohdan; Ken Nakagawa; Hiroto Egawa
Journal:  Transplant Direct       Date:  2021-07-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.